Table 1. Characteristics and radiation survival of 27 cell lines used in this study.
| Cell cycle distribution (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell line | Type | DT (hr) | G1 | S | G2/M | Relative DNA content 2n = 1b | No. of chromosomes/cellMean ± SD | X-shapec (%) | PE | SF2 | SF5 |
| D17a | OSA | 22 | 43.3 | 28.1 | 28.5 | 1.4 | 79.1±25.4 | 54 | 0.24 | 0.70 | 0.25 |
| Abrams | OSA | 19 | 49.0 | 36.8 | 14.4 | 1.6 | 108±21.0 | 15 | 0.43 | 0.85 | 0.50 |
| Morescoa | OSA | 22 | 67.5 | 28.3 | 4.20 | 1.6 | 82.4±15.9 | 38 | 0.29 | 0.81 | 0.38 |
| Gracie* | OSA | 19 | 44.4 | 38.6 | 17.0 | 1.1 | 74.3±4.8 | 5.8 | 0.23 | 0.77 | 0.33 |
| MacKinleya | OSA | 28 | 40.2 | 47.7 | 12.1 | 1.0 | 58.2±5.1 | 27 | 0.22 | 0.44 | 0.04 |
| HMPOS | OSA | 20 | 52.7 | 35.4 | 12.0 | 1.6 | 84.3±10.6 | 35 | 0.23 | 0.80 | 0.29 |
| OSA8 | OSA | 21 | 67.5 | 22.8 | 9.83 | 1.5 | 94.5±6.70 | 15 | 0.34 | 0.84 | 0.33 |
| 17CM98 | Melanoma | 22 | 62.0 | 22.7 | 15.3 | 2.1 | 155±28.5 | 1.5 | 0.23 | 0.67 | 0.20 |
| CML-6M | Melanoma | 15 | 51.9 | 34.3 | 13.8 | 1.0 | 78.6±5.24 | 2.6 | 0.61 | 0.74 | 0.27 |
| CML-10C2 | Melanoma | 21 | 50.7 | 32.2 | 17.1 | 1.4 | 105±16.6 | 6.3 | 0.19 | 0.38 | 0.02 |
| Jones | Melanoma | 14 | 55.0 | 33.5 | 11.5 | 1.2 | 81.0±3.61 | 2.5 | 0.62 | 0.66 | 0.15 |
| Parks | Melanoma | 30 | 42.3 | 17.3 | 29.9 | 1.2 | 73.7±11.5 | 3.8 | 0.15 | 0.72 | 0.17 |
| CMT-12 | Breast | 19 | 37.7 | 39.4 | 22.9 | 2.0 | 121±20.3 | 13 | 0.43 | 0.93 | 0.69 |
| CMT-27 | Breast | 18 | 42.1 | 35.2 | 22.8 | 1.1 | 76.1±20.5 | 13 | 0.50 | 0.86 | 0.39 |
| DEN-HSA | HSA | 16 | 47.7 | 36.5 | 15.7 | 1.2 | 76.9±6.67 | 6.9 | 0.44 | 0.86 | 0.40 |
| K9TCC | Bladder | 18 | 46.7 | 37.4 | 15.9 | 1.0 | 77.3±14.3 | 11 | 0.54 | 0.90 | 0.60 |
| Bliley | Bladder | 20 | 55.1 | 28.7 | 16.2 | 2.1 | 145±31.8 | 3.6 | 0.16 | 0.44 | 0.04 |
| DH82 | Histiocytic | 26 | 45.8 | 31.7 | 22.6 | 1.6 | 72.2±13.4 | 39 | 0.35 | 0.69 | 0.10 |
| Nike | Histiocytic | 25 | 42.1 | 37.9 | 20.0 | 1.4 | 64.4±102 | 30 | 0.14 | 0.19 | 0.01 |
| STSA-1 | Soft-tissue | 40 | 42.3 | 27.8 | 29.9 | 1.0 | 60.5±12.1 | 26 | 0.22 | 0.44 | 0.12 |
| CTAC | Thyroid | 15 | 53.2 | 36.7 | 10.2 | 1.2 | 81.1±13.4 | 9.6 | 0.54 | 0.80 | 0.26 |
| 1771 | Lymphoid | 24 | 66.2 | 28.5 | 5.38 | 1.1 | 56.6±3.02 | 34 | 0.65 | 0.75 | 0.27 |
| OSW | Lymphoid | 16 | 56.2 | 36.6 | 7.28 | 1.0 | 73.6±2.56 | 2.6 | 0.44 | 0.61 | 0.15 |
| CLBL1 | Lymphoid | 19 | 39.3 | 50.1 | 10.5 | 1.0 | 73.1±15.2 | 6.5 | 0.37 | 0.53 | 0.06 |
| CLL1390 | Lymphoid | 37 | 62.6 | 33.6 | 3.74 | 1.6 | 143±29.2 | 4.8 | 0.63 | 0.85 | 0.36 |
| C2 | Mast cell | 21 | 64.7 | 27.1 | 8.18 | 1.5 | 94.0±9.39 | 17 | 0.45 | 0.64 | 0.25 |
| BR | Mast cell | 36 | 69.6 | 28.9 | 1.52 | 0.9 | 73.5±7.05 | 4.5 | 0.04 | 0.56 | 0.10 |
Abbreviations: OSA, osteosarcoma; HSA, hemangiosarcoma; DT, doubling time; PE, plating efficiency; SF2, survival fraction at 2 Gy; SF5, survival fraction at 5 Gy.
aData from Maeda et al., 2012
bThe diploid amount of DNA (2n) is 1.
cPercentage of metacentric chromosome.